MTOR and renal cell carcinoma: Although mTOR inhibitors rapamycin and its analogs (rapalogs), such as temsirolimus25 and everolimus,26 have been approved for the treatment of advanced RCC, the uses of these inhibitors have had only modest successes in clinical trials;27 however, ATP-competitive mTOR inhibitors that fully inhibit both the mTOR complexes exhibit stronger antitumor effects.28